



## **ZRT Reference Range Determination**

# Table of Contents

<b>INTRODUCTION</b> .....	<b>5</b>
<b>METHYLMALONIC ACID: AN EXAMPLE OF THE INEFFECTIVENESS OF CLASSICAL REFERENCE RANGES</b> .....	<b>6</b>
GOAL.....	6
PROBLEM.....	6
POSSIBLE SOLUTIONS .....	6
<b>ZRT REFERENCE RANGE PHILOSOPHY</b> .....	<b>7</b>
<b>IMPORTANCE OF CONSIDERING SYMPTOMS WHEN DETERMINING RANGES</b> .....	<b>9</b>
<b>ESTRADIOL</b> .....	<b>11</b>
<b>ESTRONE</b> .....	<b>14</b>
<b>ESTRIOL</b> .....	<b>15</b>
<b>PROGESTERONE</b> .....	<b>16</b>
<b>TESTOSTERONE</b> .....	<b>19</b>
<b>DHEA-S</b> .....	<b>21</b>
<b>CORTISOL</b> .....	<b>23</b>
<b>ZRT LABORATORY SALIVA OBSERVED REFERENCE RANGES</b> .....	<b>26</b>
<b>REFERENCES</b> .....	<b>27</b>

# Figures

FIGURE 1. REFERENCE RANGE DETERMINED USING AVERAGE VALUE PLUS AND MINUS TWO STANDARD DEVIATIONS .....	5
FIGURE 2. HOT FLASH FREQUENCY VS. SALIVARY ESTRADIOL LEVELS.....	7
<b>FIGURE 3. VAGINAL DRYNESS VS. SALIVARY ESTRADIOL LEVELS .....</b>	<b>8</b>
FIGURE 5. TESTOSTERONE VALUES FOR PREMENOPAUSAL WOMEN WITH AND WITHOUT ANDROGEN-EXCESS SYMPTOMS .....	9
FIGURE 6. ESTRADIOL AGE-DEPENDENT REFERENCE RANGES FOR MALES .....	12
FIGURE 7. ESTRADIOL AGE-DEPENDENT REFERENCE RANGES FOR FEMALES.....	13
FIGURE 8. ESTRONE AGE-DEPENDENT REFERENCE RANGES FOR FEMALES .....	14
FIGURE 9. ESTRIOL AGE-DEPENDENT REFERENCE RANGES FOR FEMALES .....	15
FIGURE 11. PROGESTERONE AGE-DEPENDENT REFERENCE RANGES FOR MALES .....	18
FIGURE 12. PROGESTERONE DURING THE MENSTRUAL CYCLE WITHOUT CONTRACEPTIVES (IBL 2006).....	18
FIGURE 13. TESTOSTERONE AGE-DEPENDENT REFERENCE RANGES FOR MALES .....	20
FIGURE 14. TESTOSTERONE AGE-DEPENDENT REFERENCE RANGES FOR FEMALES .....	20
FIGURE 15. DHEA-S AGE-DEPENDENT REFERENCE RANGES FOR FEMALES .....	22
FIGURE 16. DHEA-S AGE-DEPENDENT REFERENCE RANGES FOR MALES.....	22
FIGURE 17. REFERENCE RANGES FOR C1, SHOWING CLASSICALLY DETERMINED RANGE VS. OBSERVED RANGE.....	24
FIGURE 18. REFERENCE RANGES FOR C2, SHOWING CLASSICALLY DETERMINED RANGE VS. OBSERVED RANGE.....	24
FIGURE 19. REFERENCE RANGES FOR C3, SHOWING CLASSICALLY DETERMINED RANGE VS. OBSERVED RANGE.....	25
FIGURE 20. REFERENCE RANGES FOR C4, SHOWING CLASSICALLY DETERMINED RANGE VS. OBSERVED RANGE.....	25


## Tables

TABLE 1. EXCUSIONS MADE FOR REFERENCE AND OPTIMAL HORMONE RANGE DETERMINATIONS .....	10
TABLE 2. NUMERICAL DATA USED FOR DETERMINING ESTRADIOL REFERENCE RANGES FOR WOMEN AND MEN.....	11
TABLE 3. CLASSICAL VS. OBSERVED RANGES FOR ESTRADIOL .....	11
TABLE 4. NUMERICAL DATA USED FOR DETERMINING ESTRONE REFERENCE RANGE FOR PREMENOPAUSAL WOMEN .....	14
TABLE 5. CLASSICAL VS. OBSERVED RANGES FOR ESTRONE .....	14
TABLE 6. NUMERICAL DATA USED FOR DETERMINING ESTRIOL REFERENCE RANGES FOR NON-PREGNANT, PRE-MENOPAUSAL WOMEN .....	15
TABLE 7. CLASSICAL VS. OBSERVED RANGES FOR ESTRIOL .....	15
TABLE 8. NUMERICAL DATA USED FOR DETERMINING PROGESTERONE REFERENCE RANGES FOR WOMEN AND MEN.....	17
TABLE 9. CLASSICAL VS. OPTIMAL RANGES FOR PROGESTERONE BY GENDER .....	17
TABLE 10. NUMERICAL DATA USED FOR DETERMINING TESTOSTERONE REFERENCE RANGES BY GENDER	19
TABLE 11. FEMALE AND MALE TESTOSTERONE RANGES.....	19
TABLE 12. CLASSICAL VS. OPTIMAL RANGES FOR TESTOSTERONE BY GENDER.....	19
TABLE 13. NUMERICAL DATA USED FOR DETERMINING DHEA-S REFERENCE RANGES FOR WOMEN AND MEN.....	21
TABLE 14. FEMALE AND MALE DHEA-S RANGES .....	21
TABLE 15. NUMERICAL DATA USED FOR DETERMINING CORTISOL REFERENCE RANGES.....	23
TABLE 16. CLASSICAL VS. OBSERVED REFERENCE RANGES FOR MORNING, NOON, EVENING, AND NIGHTTIME CORTISOL .....	23

## Introduction

This document describes the methodology used by ZRT in determining reference ranges for saliva tests. See [ZRT's Saliva Observed Reference Ranges](#) on Page 26.

For physicians and patients to obtain maximum clinical relevance from their ZRT Laboratory results, accurate and appropriate reference ranges must be provided. In classical laboratory work, reference ranges are determined by looking at a relatively large number of normal subjects with respect to the analyte of interest. A reference range is usually determined statistically by using the average value plus and minus two standard deviations. Theoretically, this range represents 90 percent of the population (5<sup>th</sup> to 95<sup>th</sup> percentile) as shown in Figure 1.



**Figure 1. Reference Range Determined Using Average Value Plus and Minus Two Standard Deviations**

The above approach to determining “normal” ranges is effective when testing patients for conditions that are present in less than five percent of the population; however, this method is insufficient for conditions found in a larger percentage of the population.

Cortisol testing, in cases of suspected Cushing’s Disease or Addison’s Disease, is an example in which results would be expected to fall outside two standard deviations of the average in the general population. This is true whether cortisol is measured in urine, blood serum, or saliva.

Conversely, stress-related adrenal dysfunction is more difficult to screen for with standard reference ranges. Low cortisol levels associated with severe fatigue and other stress-related symptoms, as seen in a significant percentage of patients testing with ZRT, suggest that inadequate stress hormone production affects many more patients than those who fit the criteria for Addison’s Disease. This makes determining the normal cortisol reference range difficult. Classical methods for determining reference ranges may lead to many individuals labeled as “normal” when in fact they may have cortisol-related symptoms that could be addressed with tighter reference ranges. An example of this concept is measurement of methylmalonic acid in determining Vitamin B12 deficiency.

## **Methylmalonic Acid: An Example of the Ineffectiveness of Classical Reference Ranges**

Urinary methylmalonic acid (MMA) is a marker for Vitamin B12 deficiency. It is an example of how a reference range determined by the mean plus and minus two standard deviations can be inadequate to screen for pathology. MMA is not related to any of the hormones measured by ZRT Laboratory, but directs us away from a one-size-fits-all style with respect to reference ranges in clinical laboratory work. Consider the following:

- When the body has insufficient levels of Vitamin B12, methylmalonic acid (MMA) in serum and urine increases.
- Many people in the general population, and nearly 20 percent of the elderly, have decreased levels of Vitamin B12.
- 20 percent of the population has a genetic defect that negatively affects the body's ability to deliver B12 to cells even if a "normal" level is present. (This fact makes MMA a better marker than B12.)
- Urinary levels of MMA are reported in micrograms per milligram of creatinine (to normalize for hydration); simply put, creatinine is involved in the reporting of MMA.
- Creatinine levels decrease with age making age-dependent reference ranges a necessity.

### **Goal**

- Determine an appropriate reference range for urinary MMA in the elderly.  
**Note:** This is not a ZRT goal, but simply an analogy for our reference range philosophy.

### **Problem**

- At least 20 percent of the population may be B12 deficient due to genetic defect. Of the remaining 80 percent, up to 20 percent of those may be B12 deficient due to an actual B12 deficiency. Therefore, it is possible that 36 percent of the total population has a B12 deficiency.
- Without genetic and serum B12 screening, the 36 percent of the population that may be B12 deficient could be included in the reference range study.
- Using a classical interpretation of a reference range, only 5 percent of the population would be classified as having an elevated urinary MMA (and, therefore, low B12 status).

### **Possible Solutions**

- Use classic reference ranges and deliver a possible 86 percent false-negative rate.
- Abandon MMA measurements in exchange for genetic screening AND Vitamin B12 measurements – very expensive and completely impractical for patient and physician.
- Adjust the "normal" range for more clinically useful results.

Laboratories measuring urinary MMA have adjusted their reference range philosophy using a cut-off of the 80<sup>th</sup> percentile instead of two standard deviations. Ultimately, reference ranges include a degree of arbitrariness, and can never include 100 percent of those with a particular condition or exclude 100 percent of those without.

## ZRT Reference Range Philosophy

A classical reference range is often of limited clinical utility. If using this approach (average, +/- two standard deviations), premenopausal estradiol reference ranges would be 0.0 – 5.0 pg/ml. If instead of this approach, we use a more aggressive reference range such as that used for urinary methylmalonic acid in the previous example, a range of 1.3 – 3.3 pg/ml is derived. By examining clinical symptoms that accompany the patient results, we can show that using the 20<sup>th</sup> and 80<sup>th</sup> percentiles gives a more clinically useful range. With respect to women's hot flash severity, as well as other estrogen-related conditions, symptoms are at their peak at estradiol levels of <1.0 pg/ml. Symptoms subside considerably as the estradiol rises to around 1.3 pg/ml. Similarly, breast tenderness is a symptom related to excessive estradiol (see Figure 4) and peaks at an estradiol of approximately 3.3 pg/ml. The idea of balancing a woman's hormone level to optimize both estrogen deficiency and estrogen excess-related symptoms is not possible when utilizing a classical reference range. A range of 1.3 – 3.3 pg/ml can be more clinically useful than the classic two standard deviation range, within which the entire rise and fall of the related symptoms occur.




Figure 2. Hot Flash Frequency vs. Salivary Estradiol Levels




Figure 3. Vaginal Dryness vs. Salivary Estradiol Levels





Figure 4. Breast Tenderness vs. Salivary Estradiol Levels

## Importance of Considering Symptoms When Determining Ranges

When normal hormone ranges are determined, individuals with hormone-related symptoms and conditions must be excluded. Reference ranges for testosterone, for example, would be inappropriately determined for premenopausal females if individuals with Polycystic Ovarian Syndrome (PCOS) or androgen-excess symptoms are not excluded.

All samples submitted to ZRT include a comprehensive, hormone-related symptom list. Patients fill out the symptom section, scoring the severity of symptoms (0-3 scale). Individuals with androgen-excess symptoms (e.g., increased facial/body hair or acne) were excluded when the female testosterone range was determined. See Figure 5.



**Figure 5. Testosterone Values for Premenopausal Women with and Without Androgen-Excess Symptoms**

The following exclusions were made for reference and optimal range determinations:

**Table 1. Exclusions Made for Reference and Optimal Hormone Range Determinations**

<b>Hormone</b>	<b>Exclusions</b>
<b>Cortisol</b>	<ul style="list-style-type: none"> <li>• Stress &gt;1</li> <li>• Morning Fatigue &gt;1</li> <li>• Evening Fatigue &gt;1</li> </ul>
<b>Estradiol</b>	<ul style="list-style-type: none"> <li>• Hot Flashes &gt;1</li> <li>• Vaginal Dryness &gt;1</li> <li>• Urinary Incontinence &gt;1</li> </ul>
<b>Progesterone</b>	<ul style="list-style-type: none"> <li>• Tender Breasts &gt;1</li> <li>• Fibrocystic Breasts &gt;1</li> <li>• Uterine Fibroids &gt;1</li> </ul>
<b>Testosterone</b>	<ul style="list-style-type: none"> <li>• Increased Body and Facial Hair &gt;1 (women only)</li> </ul>
<b>All Hormones</b>	Individuals with symptoms of hormone deficiency or excess for the hormone ranges in question

Consideration of all relevant variables was made when establishing optimal and reference ranges. The actual approach to assessing each range is complicated, involving many variables. Each hormone has been considered independently to achieve clinical usefulness. Following is a description of the philosophy and statistical methods used for the determination of reference range determination for each salivary hormone measured by ZRT.

Even with the exclusion of individuals taking supplementation and those who were excluded due to hormone-related symptoms, the following population sizes were available for the determination of ZRT reference ranges:

Reference Range Sample Sizes

Estradiol – 7,436 women, 11,681 men

Estrone – 1,107 women

Estriol – 1,107 women

Progesterone – 12,157 women, 9,257 men

Testosterone – 1,248 women, 3,021 men

DHEA-S – 10,125 women, 2,910 men

Cortisol – 2,597 (morning sample), 2,265 (noon), 2,261 (evening), and 3,405 (night)

## Estradiol

Estradiol production in women is stable throughout most of their reproductive years. During perimenopause, estradiol synthesis begins to decrease, but can also fluctuate significantly. After menopause, estradiol levels remain stable at lower levels. In men, estradiol levels are not age-dependent, and low levels have little clinical significance so the range is broader on the bottom end of the range. The 20th percentile is used for females and the 10th percentile for men.

To eliminate individuals with obvious estrogen-related conditions, women who indicated they had hot flashes, vaginal dryness, or urinary incontinence were excluded.

The tables and figures that follow indicate how estradiol reference ranges were determined.

**Table 2. Numerical Data Used for Determining Estradiol Reference Ranges for Women and Men**

Group	Mean	Median	- 2 S.D.	+ 2 S.D.	20 <sup>th</sup> Percentile	80 <sup>th</sup> Percentile
Premenopausal	2.3 pg/ml	1.9 pg/ml	0.0	5.0	1.3	3.3
Postmenopausal	1.3 pg/ml	1.0 pg/ml	0.0	3.6	0.5	1.7
Male	1.6 pg/ml	1.3 pg/ml	0.0	3.6	0.5*	2.2

\* 10<sup>th</sup> percentile is used for men

**Table 3. Classical vs. Observed Ranges for Estradiol**

Group	Classic Reference Range	Observed Range
Male	0 – 3.6 pg/ml	0.5 – 2.2 pg/ml
Premenopausal	0 – 5.0 pg/ml	1.3 – 3.3 pg/ml
Postmenopausal	0 – 3.6 pg/ml	0.5 – 1.7 pg/ml




Figure 6. Estradiol Age-Dependent Reference Ranges for Males




Figure 7. Estradiol Age-Dependent Reference Ranges for Females

## Estrone

The philosophy for optimal ranges for estrone parallels that used for estradiol (see [Estradiol](#) on Page 11.)


The tables and figure that follow indicate how the estrone reference range was determined.

**Table 4. Numerical Data Used for Determining Estrone Reference Range for Premenopausal Women**

Group	Mean	Median	- 2 S.D.	+ 2 S.D.	20 <sup>th</sup> Percentile	80 <sup>th</sup> Percentile
Premenopausal	3.4 pg/ml	2.5 pg/ml	0.0	9.0	1.6	5.0

**Table 5. Classical vs. Observed Ranges for Estrone**

Group	Classic Reference Range	Observed Range
Premenopausal	0 – 9.0 pg/ml	1.6 – 5.0pg/ml



**Figure 8. Estrone Age-Dependent Reference Ranges for Females**

## Estriol

The analytical performance for estriol is less precise at low concentrations than for the other estrogens. Therefore, estriol testing may be more useful for monitoring supplementation rather than for determining endogenous production. Estriol testing may also be desired during pregnancy when endogenous production increases.


The tables and figure that follow indicate how the estriol reference range was determined.

**Table 6. Numerical Data Used for Determining Estriol Reference Ranges for Non-pregnant, Premenopausal Women**

Group	Mean	Median	- 2 S.D.	+ 2 S.D.	20 <sup>th</sup> Percentile	80 <sup>th</sup> Percentile
Non-pregnant, Premenopausal	3.0 pg/ml	2.7 pg/ml	0.0	7.0	1.3	3.9

**Table 7. Classical vs. Observed Ranges for Estriol**

Group	Classic Reference Range	Observed Range
Non-pregnant, Premenopausal	0 – 7.0 pg/ml	0 – 7pg/ml




**Figure 9. Estriol Age-Dependent Reference Ranges for Females**

## Progesterone

The consensus from the literature is that mid-luteal salivary progesterone levels are approximately 150 pg/ml +/- 100 (see Figure 10 below). ZRT has noted similar results, but the issue of sample exclusion is uniquely difficult for progesterone.

In women, progesterone is made mainly by the corpus luteum following ovulation. Levels rise to their maximum value (in non-pregnant women) around days 19-21 of the menstrual cycle, which is when ZRT recommends sample collection in premenopausal women. It is difficult to determine whether or not ovulation has occurred in any given cycle. Literature review suggests that the rate of anovulation for any given cycle is as high as 50 percent. If the results of women who do not ovulate in the month of collection are included in a reference range study, the range will be skewed toward the low end, and will not accurately reflect mid-luteal, expected progesterone levels. Based on the combined information in the literature, and the ZRT database, women with a progesterone of <60 pg/ml were considered to be either anovulatory or not collecting during the luteal phase peak.

Women who had undergone hysterectomy or who suffered from classical progesterone deficiency symptoms (e.g., fibrocystic breast changes, breast tenderness, or uterine fibroids) were excluded from the reference range determination. Because we can show that low levels of progesterone are more strongly related to patient symptoms than are elevated progesterone (see Figure 10), the reference range is weighted more towards higher results. A less aggressive cut-off was used for the upper end of normal (30<sup>th</sup> percentile for men, postmenopausal women). Likewise, a slightly higher cut-off was used for the low end of the observed range for all men and women.



**Figure 10. Progesterone Correlation with Symptoms Weighted More Toward Progesterone Deficiency**

The tables and figures that follow indicate how the progesterone reference ranges were determined.

**Table 8. Numerical Data Used for Determining Progesterone Reference Ranges for Women and Men**

Group	Mean	Median	- 2 S.D.	+ 2 S.D.	20 <sup>th</sup> Percentile	80 <sup>th</sup> Percentile	90 <sup>th</sup> Percentile
Luteal Premenopausal	87 pg/ml	61 pg/ml	0	275	75	180	270
Postmenopausal	36 pg/ml	18 pg/ml	0	133	12*	50	100*
Men	44 pg/ml	24 pg/ml	0.0	146	15**	52	100**

**Table 9. Classical vs. Optimal Ranges for Progesterone by Gender**

Group	Classic Reference Range	Observed Range
Premenopausal	0 – 275 pg/ml	75 – 270 pg/ml
Postmenopausal	0 – 133 pg/ml	12 – 100 pg/ml*
Male	0 – 146 pg/ml	15 – 100 pg/ml**

\* Actual population percentiles were 30<sup>th</sup> and 93<sup>th</sup> percentile

\*\* Actual population percentiles were 30<sup>th</sup> and 87<sup>th</sup> percentile




Figure 11. Progesterone Age-Dependent Reference Ranges for Males




Figure 12. Progesterone During the Menstrual Cycle Without Contraceptives (IBL 2006)

## Testosterone

Testosterone levels decrease with age in both men and women. For women, many samples may be submitted from those with androgen-excess symptoms such as increased facial/body hair or acne. To exclude these individuals, only women with a score of  $\leq 1$  (for a 0–3 scale) was allowed for those symptoms for premenopausal women ages 16-45.

The tables and figures that follow indicate how the testosterone reference ranges were determined.

**Table 10. Numerical Data Used for Determining Testosterone Reference Ranges by Gender**

Group	Mean	Median	- 2 S.D.	+ 2 S.D.
Male	73 pg /ml	69 pg /ml	0.0	140

**Table 11. Female and Male Testosterone Ranges**

FEMALE	2 S.D. Ranges		Observed Ranges	
	-2 S.D.	+2 S.D.	20th %	80th %
16-30	0.0	88.0	18.0	55.0
>31	0.0	60.2	16.0	40.0
All	0.0	74.1	16.0	55.0
All results in pg/ml				

MALE	2 S.D. Ranges		Observed Ranges	
	-2 S.D.	+2 S.D.	20th %	80th %
18-30	18	205	72	148
31-50	11	159	58	120
51-70	1	128	44	94
>70	0	112	30	77
All	0	140	44	148
All results in pg/ml				

**Table 12. Classical vs. Optimal Ranges for Testosterone by Gender**

Group	Classic Reference Range	Optimal Range
Male	0 – 140 pg/ml	44 – 148 pg/ml
Female	0 – 74 pg/ml	16 – 55 pg/ml




Figure 13. Testosterone Age-Dependent Reference Ranges for Males




Figure 14. Testosterone Age-Dependent Reference Ranges for Females

## DHEA-S

DHEA levels are known to decline rapidly throughout the day. Since DHEA-S is much more slowly metabolized, it serves as a better marker for overall DHEA production, and is, therefore, the analyte tested by ZRT.

DHEA-S is known to decrease with age.<sup>1</sup> This decline makes the process of developing reference ranges challenging. An endogenous DHEA-S level of 13.3 is “normal” for a 20-year-old yet is found in only 5-10 percent of elderly males and less than 2 percent of elderly females.

Although it may seem obvious that DHEA-S levels should be reported in gender and age-specific reference ranges, the purpose of testing should also be addressed. The decline in DHEA-S with age is accompanied by an increase in related symptoms commonly seen in the aging population. These symptoms may indeed be the reason that patients or their health care providers want to test DHEA-S. In addition, physicians differ in terms of whether they believe a result within an expected age range is normal, or whether a patient’s level should be interpreted in the context of younger subjects.

Because the gradual drop in DHEA-S is often associated with symptoms of aging, a classic reference range using the mean +/- 2 standard deviations has little clinical utility. A tighter range with age and gender breakdowns was used (20<sup>th</sup> to 80<sup>th</sup> percentile).

The tables that follow indicate how the DHEA-S reference ranges were determined.

**Table 13. Numerical Data Used for Determining DHEA-S Reference Ranges for Women and Men**

Group	Mean	Median	- 2 S.D	+ 2 S.D.
Female	7.6 ng/ml	5.9 ng /ml	0.0	15.7
Male	10.3 ng/ml	8.3 ng /ml	0.0	22.6

**Table 14. Female and Male DHEA-S Ranges**

FEMALE	2 S.D. Ranges		Observed Ranges	
	-2 S.D.	+2 S.D.	20th %	80th %
18-30	0.0	25.3	6.4	18.6
31-45	0.0	16.1	3.9	11.4
46-60	0.0	11.3	2.7	8.0
61-75	0.0	7.8	1.9	5.6
All	0.0	15.7	2.0	19.0
All results in pg/ml				

MALE	2 S.D. Ranges		Observed Ranges	
	-2 S.D.	+2 S.D.	20th %	80th %
18-30	0.0	31.5	8.4	23.0
31-45	0.0	24.7	6.1	17.8
46-60	0.0	17.0	3.9	11.5
61-75	0.0	14.0	2.4	7.5
All	0.0	22.6	2.0	23.0
All results in pg/ml				

<sup>1</sup> Williams’ Textbook of Endocrinology, 2003,

Figure 15 and Figure 16 show how DHEA-S decreases with advancing age in women and men.




Figure 15. DHEA-S Age-Dependent Reference Ranges for Females




Figure 16. DHEA-S Age-Dependent Reference Ranges for Males

## Cortisol

Because of the number of factors affecting adrenal production of cortisol and the high number of people suffering from adrenal dysfunction, tighter reference ranges must be used compared to the classical model. Using the 80<sup>th</sup> percentile makes the most sense for establishing the high end of the range. With many cortisol-related symptoms able to increase production in some scenarios, and decrease them in others, a symmetrical reference range seems the best choice. Therefore, the 20<sup>th</sup> percentile mark is used for the low end of the reference ranges for all four cortisol levels measured.

To eliminate those with abnormal cortisol levels, individuals with very high levels of stress and fatigue were eliminated from consideration for C1. Overall, these symptoms were associated with slightly lower (about 4 percent) levels. Symptoms of stress and fatigue were not shown to affect B, C, and D results and were not used for exclusion in B, C, and D range determination. Individuals known to have Cushing's Disease or Addison's Disease were excluded. It is important to include the classically determined ranges for cortisol for the determination of conditions such as Cushing's Disease.

The tables and figures that follow indicate how the cortisol reference ranges were determined.

**Table 15. Numerical Data Used for Determining Cortisol Reference Ranges**

Test	Mean	- 2 S.D.	+ 2 S.D.	20 <sup>th</sup> Percentile	80 <sup>th</sup> Percentile
C1	6.3 ng/ml	0.0	14.4	3.7	9.5
C2	1.9 ng/ml	0.0	4.6	1.2	3.0
C3	1.1 ng/ml	0.0	3.2	0.6	1.9
C4	0.6 ng/ml	0.0	2.1	0.35	1.0

**Table 16. Classical vs. Observed Reference Ranges for Morning, Noon, Evening, and Nighttime Cortisol**

Test	Classical Reference Range	Optimal Range
C1	0 – 14.4 ng/ml	3.7 – 9.5 ng/ml
C2	0 – 4.6 ng/ml	1.2 – 3.0 ng/ml
C3	0 – 3.2 ng/ml	0.6 – 1.9 ng/ml
C4	0 – 2.1 ng/ml	0.35 – 1.0 ng/ml

### Morning Cortisol (C1) Reference Ranges

n = 2,269

Morning/Evening Fatigue & Stress = 0 (0-3)




Figure 17. Reference Ranges for C1, Showing Classically Determined Range vs. Observed Range

### Noon Cortisol (C2) Reference Ranges

n = 2,237




Figure 18. Reference Ranges for C2, Showing Classically Determined Range vs. Observed Range




Figure 19. Reference Ranges for C3, Showing Classically Determined Range vs. Observed Range




Figure 20. Reference Ranges for C4, Showing Classically Determined Range vs. Observed Range

## ZRT Laboratory Saliva Observed Reference Ranges

**Disclaimer:** Supplement type and dosage are for provider information and are **not** recommendations for treatment. Reference ranges are observed ranges based on collected laboratory data. For more information, see [www.zrtlab.com](http://www.zrtlab.com) or contact [info@zrtlab.com](mailto:info@zrtlab.com)

			Observed Reference Ranges (1/07)	Old Ranges	
<b>WOMEN</b>					
<b>Estradiol (pg/ml)</b>	<b>Premenopausal</b>		1.3–3.3	1–5	
	<b>Postmenopausal</b>		0.5–1.7	1–1.5	
	<b>Supplement (12–24 Hrs.)</b>	Estradiol Patch (0.05 mg)		0.8–2	
		Hormonal Contraceptives		0.5–2.2	
		Oral Estradiol (.5–1.0 mg)		1.2–3.9	1.5–10
		Oral Premarin* (0.625 mg)		0.9–3.7	
		Topical Bi-est 4:1, (0.6–1.25 mg)		2.4–11.6	1.5–10
Topical Estradiol (0.5–1.0 mg)		2.9–35.5			
<b>Progesterone (pg/ml)</b>	<b>Premenopausal</b>	Luteal	75–270	100–600	
		Follicular	12–100		
	<b>Postmenopausal</b>		12–100	25–100	
		<b>Supplement (12–24 Hrs.)</b>	Hormonal Contraceptives	10–53	
		Oral Progesterone (100 mg)	30–300	100–1000	
		Topical Progesterone (20 mg)	200–3000	500–3000	
<b>Testosterone (pg/ml)</b>		All Ages	16–55	20–50	
		Ages 16–30	18–55		
		Ages >30	16–47		
	<b>Supplement (12–24 Hrs.)</b>	Hormonal Contraceptives	13–45		
		Topical Testosterone (0.3–0.5 mg)	22–86	n/a	
<b>DHEA-S (ng/ml)</b>		All Ages	2–19	3–10	
		Ages 16–30	6.4–18.6		
		Ages 31–45	3.9–11.4		
		Ages 46–60	2.7–8		
		Ages 61–75	2–6		
	<b>Supplement (12–24 Hrs.)</b>	Oral DHEA (5–10 mg)	2.8–8.6		
		Topical DHEA (5 mg)	3–8		
<b>Estrone (pg/ml)</b>			1.6–5	2–10	
<b>Estriol (pg/ml)</b>	<b>Premenopausal</b>		< 7	3–7	
	<b>Postmenopausal</b>				
	<b>Supplement (12–24 Hrs.)</b>	Oral Estriol	5–20	5–20	
		Topical Estriol	5–100	5–100	
<b>MEN</b>					
<b>Estradiol (pg/ml)</b>			0.8–2.2	0.5–1.5	
<b>Progesterone (pg/ml)</b>			15–100	25–100	
		Topical progesterone (5–10 mg)	42–650		
<b>Testosterone (pg/ml)</b>		All Ages	44–148	50–200	
		Ages 16–30	72–148		
		Ages 31–50	58–120		
		Ages 51–70	44–94		
		Ages >70	30–77		
	<b>Supplement (12–24 Hrs.)</b>	AndroGel* (25–50 mg)	1300–3700		
		Topical Testosterone (5–10 mg)	115–800	200–500	
<b>DHEA-S (ng/ml)</b>		All Ages	2–23	3–10	
		Ages 16–30	7–23		
		Ages 31–45	6–18		
		Ages 46–60	4–11.5		
		Ages 61–75	2.4–7.5		
	<b>Supplement (12–24 Hrs.)</b>	Oral DHEA (25 mg)	6–17		
		Topical DHEA (10 mg)	4–15		
<b>Estrone (pg/ml)</b>			0–3	0–3	
<b>Estriol (pg/ml)</b>			0–3	0–3	
<b>WOMEN AND MEN</b>					
<b>Cortisol (ng/ml)</b>	<b>C1</b>	Morning	3.7–9.5	3–8	
	<b>C2</b>	Noon	1.2–3	2–4	
	<b>C3</b>	Evening	0.6–1.9	1–2	
	<b>C4</b>	Night	0.4–1	0.5–1.5	

\* Other names and brands may be claimed as the property of others.

Copyright © 2007, ZRT Laboratory, LLC. All rights reserved.

## References

- Chatterton Jr., Robert T.; Mateo, Esnar T.; Hou, Nanjiang; Rademaker, Alfred W.; Acharya, Simbi ; Jordan, V. Craig ; and Morrow, Monica. "Characteristics of Salivary Profiles of Oestradiol and Progesterone in Premenopausal Women." Journal of Endocrinology 186 (2005): 77-84.
- Choe, Jung K.; Firyal S. Khan-Dawood; and Dawood, M. Yusoff. "Progesterone and Estradiol in the Saliva and Plasma During the Menstrual Cycle." American Journal of Obstetrics and Gynecology 147.5 (1983): 557-562.
- Kirschbaum, C. K.; Read, G. F.; and Hellhammer, D. H.. Assessment of Hormones and Drugs in Saliva in Biobehavioral Research. Seattle: Hogrefe & Huber, 1992.
- Lenton, E. A.; Gelsthorp, C. H.; and Harper, R. "Measurement of Progesterone in Saliva Assessment of the Normal Fertile Range Using Spontaneous Conception Cycles." Clinical Endocrinology 28 (1988): 637-646.
- Li, T. C.; Lenton, E. A.; Dockery, P.; Rogers, A. W.; and Cooke, I.D. "The Relation Between Daily Salivary Progesterone Profile and Endometrial Development in Luteal Phase of Fertile and Infertile Women." British Journal of Obstetrics and Gynaecology 96 (1989): 445-453.
- Saliva Diagnostics. Hamburg: IBL Immuno-Biological Laboratories, 2006.
- Vuorento, T.; Lahti, A.; Hovatta, O.; and Huhtaniemi, I.. "Daily Measurements of Salivary Progesterone Reveal a High Rate of Anovulation in Healthy Students." Scand J Clin. Lab Invest. 49 (1989): 395-401.
- Wong, Y. F., Mao, K.; Panesar, N.S.; Loong, E.P.L.; and Chang, A.M.Z. "Salivary Estradiol and Progesterone During the Normal Ovulatory Menstrual Cycle in Chinese Women." European Journal of Obstetrics and Gynecology and Reproductive Biology 34 (1990): 129-135.
- Yu-Cai, Lu, M.D.; Gillian R. Bentley, Ph.D.; Peter H. Gann, M.D., Sc.D.; Kelly R. Hodges, B.S.; and Robert T. Chatterton, Ph.D. "Salivary Estradiol and Progesterone Levels in Conception and Nonconception Cycles in Women: Evaluation of a New Assay for Salivary Estradiol." Fertility and Sterility 71.5 (1999): 863-868.